Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-03-08
2005-03-08
Wax, Robert A. (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C435S183000
Reexamination Certificate
active
06864237
ABSTRACT:
The present invention provides methods of preventing organ destruction and shut-down due to shock in a patient suffering from sepsis or at risk for sepsis, comprising administering adrenomedullin and adrenomedullin binding protein-1 to the patient. Also provided are compositions containing adrenomedullin and adrenomedullin binding protein-1 or precursors, in a pharmaceutically acceptable carrier.
REFERENCES:
Fowler et al., “The cardiovascular response in sepsis: Proposed mechanisms of the beneficial effect of adrenomedullin and its binding protein (Review)”, Apr. 17, 2002, 9, 443-449.*
Elsasser T.H. et al., “Adrenomedullin binding protein in the plasma of multiple species: characterization by radioligand blotting”; Endocrinol 140:4908-4911, 1999.
Shindo T. et al., “Hypotension and resistance to lipopolysaccharide-induced shock in transgenic mice overexpressing adrenomedullin in their vasculature”; Circulation 101:2309-2316, 2000.
Wichterman K.A. et al., “Sepsis and septic shock: a review of laboratory models and a proposal”; J Surg Res 29:189-201, 1980.
Wu R. et al., “Adrenomedullin and adrenomedullin binding protein-1 downregulate TNF-alpha in macrophage cell line and rat Kupffer cells”; Regul Pept 112:19-26, 2003.
Yang S et al., “Novel approach to prevent the transition from the hyperdynamic phase to the hypodynamic phase of sepsis: The role of adrenomedullin and adrenomedullin binding protein-1”; Crit Care Med. 29 (12, Suppl.) abst. A12, Dec. 2001.
Yang S. et al., “Novel approach to prevent the transition from the hyperdynamic phase to the hypodynamic phase of sepsis: Role of adrenomedullin and adrenomedullin binding protein-1”; Ann Surg 236:625-633, 2002.
Yang S. et al., “Mechanisms of the beneficial effect of adrenomedullin and adrenomedullin-binding protein-1 in sepsis: down-regulation of proinflammatory cytokines”; Crit Care Med 30:2729-2735, 2002.
Amster Rothstein & Ebenstein LLP
Mayer Suzanne M.
Wax Robert A.
LandOfFree
Treatment of shock using adrenomedullin and adrenomedullin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of shock using adrenomedullin and adrenomedullin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of shock using adrenomedullin and adrenomedullin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3368162